Pharma Mar S.A.

Investor Presentation • Jul 27, 2022

1H 2022 Results Presentation

Madrid, July 28th 2022

Disclaimer

This presentation might include forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity, results of operation, clinical program, plans and objectives of Pharma Mar, S.A. ("PharmaMar" or the "Company"). These forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "endeavor," "anticipate," "project," "estimate," "intend," "continue" or "believe" or the negatives thereof or other variations thereon or comparable terminology. These forward-looking statements are based on the expectations of management under current assumptions at the time of this presentation, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to materially differ from those contained in the forward-looking statements. All forward-looking statements in this presentation apply only as of the date made. Except as required by law, the Company is not obligated to, and does not intend to, update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. To the extent that this presentation contains market data, industry statistics and other data that have been obtained from, or compiled from, information made available by third parties, the Company has not independently verified their data.

• 1. FINANCIAL HIGHLIGHTS
• 1. OPERATIONAL UPDATE
• 1. US UPDATE
• 1. Q&A & CLOSING REMARKS

Director Capital Markets and Investor Relations

The plan for growth On track to deliver value to shareholders

FURTHER DEVELOPMENT WITH LURBINECTEDIN

OTHER DRUGS DEVELOPMENT

• Phase 3 trial with lurbinectedin in SCLC for EU approval and US confirmatory
• Phase 3 trial with lurbinectedin in other indications
• Potential lurbinectedin approvals in other countries
• 2 Phase 2 trials for PM14 planned to start in 2021 and 2022
• 2 new compounds to enter Phase 1
• CORPORATE DEVELOPMENT
• Looking for in-licensing products to market in EU
• Profitable with robust cash position

1. FINANCIAL HIGHLIGHTS

• 1. OPERATIONAL UPDATE
• 1. US UPDATE
• 1. Q&A & CLOSING REMARKS

Mª Luisa de Francia Chief Financial Officer

Main financial figures Revenues Evolution (€mn)

Main financial figures

Increasing R+D Investment 39% compared to June'21 (€mn)

Cash position Solid net cash position(€mn)

• 1. FINANCIAL HIGHLIGHTS
• 1. OPERATIONAL UPDATE
• 1. US UPDATE
• 1. Q&A & CLOSING REMARKS

Luis Mora Managing Director

Pipeline Oncology

				Phase 1	Phase 2	Phase 3	Market
	Soft tissue sarcoma	nd / 3rd 2 line	Monotherapy
	Ovarian cancer	nd / 3rd 2 line	+ Doxil (PLD)
	R/R Multiple Myeloma(1)	rd/4th 3 line	+ Dexamethasona
	Small cell lung cancer (SCLC)	nd 2 line USA	Monotherapy
	Small cell lung cancer Maintenance	st 1 line maint.	+ Atezolizumab		IMforte
	Small cell lung cancer 2nd line (LAGOON)	nd 2 line	Lurbi / Lurbi + Irinotecan Vs. Topotecan or Irinotecan		LAGOON
	Mesothelioma	nd / 3rd 2 line	+ IO		SEALIGHT (planned)
	Small cell lung cancer	nd 2 line	+ Irinotecan
	Small cell lung cancer	2 nd line	+ Atezolizumab
Ecubectedin	Solid tumors		Monotherapy
	Soft tissue sarcoma(2)		Combination radiation
(PM14)	Prostate cancer(2)		Monotherapy
	Solid tumors		Combination Trials

Oncology: Lurbinectedin

Filings and reimbursement	Countries	Estim. date
Dossiers filed for approval (SCLC)	UK, Switzerland, Brazil, Mexico, Argentina, Colombia	Dic'22-1Q'23
Negotiating reimbursements	Canada, Singapore, UAE, Australia, Qatar	NA

	Countries
Early access program	France, China, others

Clinical update:

Trials	Status	End Date
LAGOON Trial (SLCL) 2L	Recruiting	2025
IMforte Trial (SCLC) 1L Maintenance	Recruiting	2025
Mesothelioma (Lurbi+IO) 2L	To start 2022

: RNAi

			Phase 1	Phase 2	Phase 3	Market
Tivanisiran (SYL1001)	Dry eye disease (associated to Söjgren)	Activity		PIVO 1
	Dry eye disease	Security		FYDES
SYL18001	Macular degeneration

Virology

Plitidepsin SARS-CoV-2 Treatment NEPTUNO

New trial planned: to start a phase II trial in immunosuppressed patients

• 1. FINANCIAL HIGHLIGHTS
• 1. OPERATIONAL UPDATE

3. US UPDATE

1. Q&A & CLOSING REMARKS

Pascal Besman Chief Operating Officer of Pharmamar US

Lurbinectedin Recent studies

First Prospective Real World data, coming from Named Patient Program

• Heavily pre-treated SCLC (n=43) and MPM (n=52)
• Mostly ≥3rd line
• SCLC 72% Resistant/Refractory
• Cross trial comparison of SCLC sees lurbinectedin ORR 16% vs. Topotecan ORR 5% refractory, 17% sensitive
• Study demonstrates that lurbinectedin induces a relative reduction of circulating classical monocytes, which "suggests that the combination of lurbinectedin with immunotherapy might be efficacious."

Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States, B Rengarajan et al Data (using Flatiron HER database)

• Pts treated with lurbinectedin between June 2020 (FDA Approval) and October 2021. However, presentation will be data up to April 2022
• Comparing abstract to final presentation, can see that as data has matured, fewer 3-4L pts now and more 2L
• Should expect to see an increase in average cycles as more 2L patients
• Reflects that physicians are comfortable using lurbinectedin in any patient, and broadly in 2nd line.

Lurbinectedin Emerging lurbinectedin ISTs; Broadening reach in SCLC, and beyond SCLC

Combo radiation in SCLC, Emory (TiP poster at IASLC)

PHARMACLIN, Real World data from ATU in France

Durvalumab + (Lurbinectedin or Topotecan) in rSCLC; Mayo/NCI

• 1. FINANCIAL HIGHLIGHTS
• 1. OPERATIONAL UPDATE
• 1. US UPDATE
• 1. Q&A & CLOSING REMARKS

José Luis Moreno Director Capital Markets and Investor Relations